[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"smoking-cessation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:smoking-cessation":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,118,0,25,[9,43,76,100,129,151,174,194,215,245,266,287,307,330,351,372,393,419,443,465,484,508,530,556,581],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053612","phase-4-modifying-progesterone-and-estradiol-levels-to-prevent-postpartum-cigarette-smoking-relapse-and-reduce-secondhand-smoke-exposure-in-infants-and-children-100053612",false,"NCT04783857","Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children","Inclusion Criteria:\n\n* Ability to provide informed consent,\n* Aged 18 to 45 years old\n* Self-reported stable physical and mental health\n\n  1. self-report uncomplicated pregnancy at gestational week 30 or beyond, or\n  2. self-report the birth of a child within the past 6 months\n* History of ≥ 4 cigarettes per month during the six months prior to pregnancy\n* At enrollment, self-report of motivation to become and\u002For remain abstinent after delivery ≥ 6 on a 10 point Likert-type scale\n* Willingness to protect against pregnancy following day 0 to week 12 of the study\n* Participants must live in the continental US and have a device to fully participate in the protocol\n\nExclusion Criteria:\n\n* Current daily use of nicotine replacement therapy or smoking cessation medications, with the exception of e-cigarettes\n* Current major depressive disorder based on the Patient Health Questionnaire-9 (PHQ-9) and the Beck Depression Inventory\n* Contraindication to progesterone treatment (e.g., current use of drugs that may inhibit CYP3A4; current or history of deep vein thrombosis, pulmonary embolus, clotting or bleeding disorder, hypertension, stroke, heart disease, or liver dysfunction or disease; or peanut allergy),\n* Current or within the past 3 months treatment for illicit drug use or alcohol use\n* Any condition or issue that, in the opinion of the clinical team, precludes participation in the trial.","FEMALE","18 Years","45 Years",{"count":20,"type":21},171,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The investigators aim to address the following specific aims:\n\n* Determine the efficacy of Prog in preventing postpartum smoking relapse and reducing smoking relapse risk factors.\n* Examine the effects of this maternal smoking intervention on infant health.\n* Examine racial and ethnic differences in intervention outcomes.",[27,28,29],"Smoking","Smoking Cessation","Smoking Reduction","RECRUITING","2026-07-09",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2022-04-14",{"date":38,"type":21},"2027-06-02",{"name":40,"class":41},"University of Minnesota","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":51,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":42},"100053678","phase-4-varenicline-and-accelerated-transcranial-magnetic-stimulation-tms-for-quitting-nicotine-use-pilot-study-100053678","NCT07145866","Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)","Evaluation of Varenicline and Accelerated TMS for Reduction of Nicotine Use","V-TMS","Inclusion Criteria:\n\n* Age ≥ 18 and ≤65;\n* The ability to give written, informed consent;\n* Fluency in English;\n* Reported interest in quitting nicotine vaping or smoking within the next month;\n* Nicotine dependence, as defined by a score of ≥4 on the 10-question E-cigarette Dependence Inventory (ECDI) or Fagerström Test for Nicotine Dependence (FTND);\n* Smoke or vape nicotine daily for at least the past 90 days, as confirmed by self-report and timeline follow-back methods;\n* Saliva cotinine \\>30ng\u002FmL;\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding;\n* Use of smoking cessation pharmacotherapy in the past month;\n* Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study;\n* Prior adverse drug reaction to varenicline;\n* Contraindication to D-Cycloserine (including allergy to D-Cycloserine, significant renal impairment or known kidney disease, pregnancy)\n* Receiving or planning to receive other TMS treatments or investigational drugs during course of participation\n* Contraindications to TMS (including seizures, metallic implants, severe existing tinnitus, etc.);\n* Contraindications to MRI (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia);\n* Inpatient psychiatric hospitalization or suicide attempts in the past six months, or recent active suicidal ideation or suicidal behavior identified at enrollment or baseline visits;\n* History of seizures and\u002For history of TBI subtypes associated with elevated seizure risk (e.g. penetrating injury and intraparenchymal hemorrhage)\n* History of unstable neurological illness or major medical illness, such as epilepsy or renal impairment, in the past six months, unless clearly resolved;\n* In the opinion of the investigators, evidence of active problem substance use severe enough to compromise ability to safely participate;\n* In the opinion of the investigators, unable to safely participate in this study and\u002For provide reliable data (e.g., claustrophobia, unable to tolerate TMS or MRI procedures, etc.).","ALL","65 Years",{"count":54,"type":21},30,[24],"The goal of this clinical trial is to learn if a combination of varenicline and enhanced accelerated Transcranial Magnetic Stimulation (aTMS) works to help adults quit using nicotine products. Researchers will compare varenicline + active aTMS with a single dose of D-Clycloserine to varenicline + sham (inactive) aTMS with a placebo pill to see the effect of enhanced aTMS on reaching abstinence. The main question it aims to answer is: Does receiving active enhanced aTMS + varenicline lead to higher abstinence rates and lower nicotine craving?\n\nParticipants will be asked to:\n\n* Complete 2 brain MRI scans\n* Take varenicline every day for 12 weeks\n* Quit using nicotine products at the end of the second week of varenicline\n* Complete one day of up to 20 TMS treatments\n* Take a single dose of D-Cycloserine medication on the day of TMS treatment\n* Complete 12 brief, weekly follow-up visits\n* Complete a brief daily survey each day that they take the study drug",[58,59,60,28,61],"Nicotine Dependence","Transcranial Magnetic Stimulation","Vaping","Smoking (Tobacco) Addiction",[60,27,63,64,65,66,59,67,68],"Nicotine","Adults","Cessation","Varenicline","TMS","D-Cycloserine",{"date":33,"type":34},{"date":71,"type":21},"2026-08",{"date":73,"type":21},"2027-12",{"name":75,"class":41},"Massachusetts General Hospital",{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":51,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100625191","phase-4-my-path-to-quit-tobacco-100625191","NCT07419425","My Path to Quit Tobacco","Comparing Three Multicomponent Interventions to Help Adults Quit Smoking","Inclusion Criteria:\n\n* self-identify as Black\n* smoke cigarettes (greater than or equal to 1 cigarette on greater than or equal to 4 days\u002Fweek)\n* motivated to quit smoking\n* willing to discontinue any non-study smoking cessation pharmacotherapy use during study treatment.\n\nExclusion Criteria:\n\n* currently taking bupropion for non-smoking cessation reasons",true,"21 Years",{"count":86,"type":21},1550,[24],"The overarching goal of this program of research is to reduce smoking-related health disparities by increasing smoking cessation among Black adults. The goal of this research proposal is to determine whether more intensive, culturally specific, evidence-based interventions are more effective at promoting long-term cessation and other key patient-centered outcomes compared to the usual evidence-based standard of care: services provided by a state-run quitline. This study compares the relative effectiveness of three different treatments (Standard, Intensive, and Intensive Incentivized) on long-term smoking cessation (biochemically confirmed abstinence from combusted tobacco at 26-weeks post-target quit day) among Black adults who smoke and want to quit.",[28],"2026-06-30",{"date":92,"type":34},"2026-07-01",{"date":94,"type":21},"2026-07",{"date":96,"type":21},"2030-01",{"name":98,"class":41},"University of Wisconsin, Madison",5,{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":42},"100642609","promoting-smoking-cessation-in-the-community-via-quit-to-win-contest-2026-engagement-focused-genai-based-chatbot-for-real-time-smoking-cessation-support-100642609","NCT07649044","Promoting Smoking Cessation in the Community Via \"Quit to Win\" Contest 2026: Engagement-Focused GenAI-based Chatbot for Real-Time Smoking Cessation Support","Building Capacity and Promoting Smoking Cessation in the Community Via \"Quit to Win\" Contest 2026: Real-time Smoking Cessation Instant Messaging Support Using a Engagement-Focused Large Language Model (LLM)-Based Chatbot","QTW2026","Inclusion Criteria:\n\n1. Hong Kong residents aged 18 years or above\n2. Smoke at least one cigarette (including heated tobacco products) per day or use an e-cigarette daily in the preceding 3 months\n3. Able to communicate in Cantonese (including reading and writing Chinese)\n4. Saliva cotinine level ≥30 ng\u002FmL\n5. Intention to quit or reduce smoking\n6. Have WhatsApp installed\n7. Able to use WhatsApp for communication\n\nExclusion Criteria:\n\n1. Smokers who have communication barriers (either physical or cognitive)\n2. Smokers who are currently participating in other smoking cessation programs or services",{"count":109,"type":21},998,[111],"NA","The goal of this trial is to learn if chatbot-based instant messaging works to help smoking cessation in general adult smokers. It will also learn about the experience, attitude, and perception of using an LLM-based chatbot. The main questions it aims to answer are:\n\n1. Will an engagement-focused LLM-based chatbot smoking cessation intervention have a non-inferior validated abstinence rate than the control group?\n2. Will an LLM-based chatbot smoking cessation intervention have a non-inferior self-reported abstinence rate, smoking reduction rate, and smoking cessation services use rate than the control group?\n\nResearchers will compare an LLM-based chatbot smoking-cessation intervention to a human-led instant messaging support group (brief advice based on AWARD and personalised active referral) to determine whether chatbot-based instant messaging support promotes smoking cessation.\n\nParticipants in the intervention group will receive:\n\n1. AWARD advice\n2. Personalised active referral\n3. 12 weeks of chatbot-based instant messaging support (via WhatsApp)",[28],[115,116,117,118,119],"Large-language model","Chatbot","Smoking cessation","Digital health","Engagement","NOT_YET_RECRUITING","2026-06-26",{"date":90,"type":34},{"date":124,"type":21},"2026-06-27",{"date":126,"type":21},"2028-06-30",{"name":128,"class":41},"The University of Hong Kong",{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":42},"100625283","preliminary-effectiveness-of-enhanced-text-message--incentives-100625283","NCT07420621","Preliminary Effectiveness of Enhanced Text Message + Incentives","Preliminary Studies on Implementation of Smoking Cessation Interventions for Low-Income Women","Inclusion Criteria:\n\n* Pregnant women aged: 18+\n* Enrolled in the Special Supplemental Nutrition Program for women, Infants, and Children (WIC) or Medicaid (or applied\u002Fapplying)\n* Self-reported current daily smokers\n* Able to communicate in English\n* Access to a mobile phone capable of receiving text messages\n\nExclusion Criteria:\n\n* Not at all interested in quitting\n* Smoke less than 24 days in the past month\n* Greater than 30 weeks gestation",{"count":137,"type":21},50,[111],"This study is a preliminary evaluation of a smoking cessation intervention designed for pregnant women that combines text message support and financial incentives.\n\nThe aims of this study are to determine the preliminary feasibility and acceptability of text message + incentives (intervention) vs. text message only (control).",[28,141],"Pregnancy",[28,143],"Maternal Health",{"date":90,"type":34},{"date":146,"type":34},"2026-04-09",{"date":148,"type":21},"2026-08-30",{"name":150,"class":41},"University of Kansas Medical Center",{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100496608","ending-tobacco-use-through-interactive-tailored-messaging-for-cambodian-people-living-with-hivaids-100496608","NCT05746442","Ending Tobacco Use Through Interactive Tailored Messaging for Cambodian People Living With HIV\u002FAIDS","Ending Tobacco Use Through Interactive Tailored Messaging for Cambodian People Living With HIV\u002FAIDS (Project END-IT)","ProjectENDIT","Inclusion Criteria:\n\n* 1\\) being aged ≥18 years\n* 2\\) being HIV-positive\n* 3\\) self-reporting as a current combustible cigarette smoker (smoked ≥100 cigarettes in lifetime and currently smoke ≥1 cigarettes\u002Fday)\n* 4\\) willing to set a date for a quit attempt within 2 weeks of study enrollment\n* 5\\) being able to provide written informed consent to participate\n* 6\\) being able to read Khmer (score ≥4 points on the Rapid Estimate of Adult Literacy in Medicine-Short Form\n\nExclusion Criteria:\n\n* 1\\) history of a medical condition that precludes use of nicotine replacement therapy\n* 2\\) physician\u002Fclinician deemed ineligible to participate based on medical or psychiatric condition\n* 3\\) enrolled in another cessation program or use of other cessation medications.",{"count":160,"type":21},800,[111],"The goal of this research study is to test how well an automated text messaging smoking treatment program helps smokers with HIV quit smoking.",[28,164],"HIV","2026-06-24",{"date":121,"type":34},{"date":168,"type":34},"2023-01-11",{"date":170,"type":21},"2027-09-30",{"name":172,"class":41},"H. Lee Moffitt Cancer Center and Research Institute",3,{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":83,"sex":51,"minAge":17,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":190,"leadSponsor":192,"locationsCount":42},"100639319","adaptive-mobile-interventions-to-reduce-cancer-risk-behaviors-100639319","NCT07585357","Adaptive Mobile Interventions to Reduce Cancer Risk Behaviors","Inclusion Criteria:\n\n* live in the U.S.;\n* are between 18 and 40 years of age;\n* own a smartphone with iOS and Android operating system and GPS capabilities;\n* are carrying smartphone every day;\n* are willing to participate in the study for 44 days and give the research team access to the phone GPS data;\n* have smoked ≥100 cigarettes in the participant's life and currently smoke at least 3 cigarettes per day on 5 or more days of the week;\n* are planning to quit smoking within the next 30 days.\n\nExclusion Criteria:\n\n* None","40 Years",{"count":182,"type":21},7,[111],"Tobacco use remains the leading cause of preventable death, causing over 400,000 annual deaths in the United States alone. Smartphone-based interventions, particularly those leveraging real-time adaptive messaging, represent a promising yet underutilized approach to delivering personalized tobacco and cannabis treatment. The investigator's ongoing NCI funded micro-randomized trial (MRT; R01 CA246590) has shown initial feasibility in reducing smoking urges through situationally tailored cognitive-behavioral therapy (CBT) and mindfulness-based acceptance and commitment-based therapy (ACT) messages triggered by real-time contextual data (e.g., geolocation, momentary stress). To advance from a static MRT framework to a dynamic, data-driven just-in-time adaptive intervention (JITAI), this project aims to develop, test, and refine a reinforcement learning (RL) algorithm that can continuously adapt to user needs in real-time, enhancing treatment outcomes for various tobacco and cannabis products.\n\nTo ensure optimal usability and engagement, the investigators will conduct user-centered testing with the developed RL-based intervention delivery in one cohort (N=7) over 45 days. This will include usability assessment via the System Usability Scale, analysis of app interaction metrics, and semi-structured interviews to gather feedback for refining message content, timing, and design.",[28],"2026-06-23",{"date":188,"type":34},"2026-06-25",{"date":94,"type":21},{"date":191,"type":21},"2026-09",{"name":193,"class":41},"Johns Hopkins Bloomberg School of Public Health",{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":51,"minAge":84,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":42},"100616095","pascal-feasibility-study-100616095","NCT07301151","PASCAL Feasibility Study","Feasibility of Using a Conversational Agent for Promoting Smoking Cessation Treatment Utilization","Inclusion Criteria:\n\n* Identify as Black or African American\n* Be at least 21 years of age\n* Meet a minimum smoking amount\n* Be willing to make a quit attempt in the next 30 days\n* Have a smartphone capable of downloading and running the study app\n* Be able to upload data from the app\n* Agree to receive text message reminders about study activities\n* Be a native English speaker\n* Reside in Minnesota.\n\nExclusion Criteria:\n\n* Medicinal nicotine use would require careful monitoring by a healthcare professional\n* Medical condition or medication used likely to significantly interfere with study outcomes or to be significantly affected by changes in smoking behavior\n* Are pregnant or breastfeeding",{"count":202,"type":21},120,[111],"The goal of this randomized study is to assess if a conversational agent (or chatbot) that the investigators have developed to help with quitting smoking is acceptable to people trying to quit smoking and to also collect initial information regarding its effectiveness.\n\nIn this study, some participants trying to quit smoking will be provided with this chatbot while other participants will not be",[28,61],[207,208],"cigarette smoking","chatbot",{"date":165,"type":34},{"date":211,"type":34},"2026-06-11",{"date":213,"type":21},"2027-06-30",{"name":40,"class":41},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":42},"100630449","phase-2-a-study-of-vagal-nerve-stimulation-in-conjunction-with-nrt-for-smoking-cessation-100630449","NCT07487818","A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation","Using Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation","Inclusion Criteria:\n\n* 18 years of age or older at the time of consent.\n* Currently smoking at least 10 cigarettes\u002Fday\n* Motivated to stop smoking (on a scale of 0 to 10, motivation must be 3 or above);\n* Ability to participate fully in all aspects of the study.\n* Have the ability to provide informed consent.\n* Have no contraindicating comorbid health conditions that would interfere with study participation, as determined by the clinical investigators.\n\nExclusion Criteria:\n\n* Patients with a current moderate\u002Fsevere depression as assessed by a score of ≥10 on the Patient Health Questionnaire-9 (PHQ-9).\n* Patients who are or have used an investigational drug within the past 30 days.\n* Patients who are currently using medication(s) known to interact with varenicline.\n* Patients who have clinically significant acute\u002Fchronic progressive or unstable neurologic, hepatic, renal, cardiovascular, psychological, respiratory, or metabolic disease.\n* Patients with a known allergy to nicotine patches or varenicline.\n* Patients with a personal history of acute pancreatitis, hypoglycemia, acute kidney injury or impairment of renal function, type 1 diabetes or diabetic ketoacidosis, and\u002For severe gastrointestinal disease such as gastroparesis.\n* Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device.\n* Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)\n* Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)\n* Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia\n* Patients who have a metallic device such as a stent, bone plate, or bone screw implanted at or near your neck\n* Patients who are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone).\n* Women who are pregnant or lactating, or who are of childbearing potential and are likely to become pregnant during the medication phase but are not willing to use a reliable form of contraception, will also be excluded.\n\n  1. Reliable forms of contraception include oral contraception, diaphragm or condom (with spermicide), injections, intrauterine devices, surgical sterilization, and abstinence. The study does not include vulnerable populations.\n  2. Specifically, the study does not include fetuses, neonates, pregnant women, children (\\\u003C18 years of age), prisoners, institutionalized individuals, or other vulnerable populations.\n\n  i. All female participants of childbearing potential must have a negative pregnancy test and must agree to use approved contraception during study participation.",{"count":223,"type":21},150,[225,226],"PHASE2","PHASE3","The purpose of this study is to provide preliminary evidence for the efficacy of 12 weeks of vagal nerve stimulation (VNS) and nicotine replacement therapy (NRT) for increasing smoking abstinence rates.",[28],[230,231,232,233,234,235,236],"nicotine dependence","smoking","vagal nerve stimulator","VNS","varenicline","nicotine replacement therapy","nicotine patches","2026-06-18",{"date":186,"type":34},{"date":240,"type":34},"2026-04-15",{"date":242,"type":21},"2027-05-31",{"name":244,"class":41},"Mayo Clinic",{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":261,"leadSponsor":263,"locationsCount":42},"100550088","pain-and-smoking-study---interactive-voice-response-100550088","NCT06442514","Pain and Smoking Study - Interactive Voice Response","Enhancing an Intervention for Smokers With Chronic Pain Using IVR: A Randomized Clinical Trial of Smoking Cessation Counseling for Veterans","PASS-IVR","Inclusion Criteria:\n\n* being an enrolled Veteran at VACHS;\n* current tobacco use;\n* willingness to make a quit attempt;\n* significant chronic pain defined as \\>\u002F=4 on the pain intensity portion of the Brief Pain Inventory (BPI) for more than 90 days.\n\nExclusion Criteria:\n\n* active diagnosis of dementia or psychosis in medical record;\n* severely impaired hearing or speech;\n* lack of telephone access;\n* enrollment in concurrent research study that might affect main outcomes of this study;\n* terminal illness;\n* non-English speaking;\n* pregnancy;\n* provider advising against exercise;\n* planned surgeries; and\n* clinically significant depressive symptoms (\\>10 PHQ-9).",{"count":254,"type":21},220,[111],"PASS2 aims to expand upon the recently completed study (PASS intervention), which tested the telephone delivery of a cognitive behavioral intervention (CBI). This study will use Interactive Voice Response (IVR) to optimize the intervention's effectiveness for smoking cessation among Veteran smokers with chronic pain.",[27,258,28],"Pain",{"date":186,"type":34},{"date":33,"type":21},{"date":262,"type":21},"2028-05-31",{"name":264,"class":265},"VA Office of Research and Development","FED",{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":51,"minAge":84,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":42},"100561845","phase-4-the-options-2-study-100561845","NCT06595459","The Options 2 Study","A Randomized Comparative Effectiveness Trial of Nicotine Pouches for Cigarette Substitution: A Question of Public Health","Inclusion Criteria:\n\n* ≥ 21 years old (i.e., able to legally purchase tobacco products)\n* able to read and communicate in English\n* no plans to quit smoking in the next 30 days\n* willing to stop using nicotine replacement or varenicline\n* willing to stop using bupropion (i.e., Wellbutrin, Zyban) if they are currently using it only for smoking cessation\n* smoking ≥ 5 cigarettes per day for the past 6 months\n* exhaled carbon monoxide ≥ 6 ppm\n* no nicotine pouch or smokeless tobacco (including snus) use within the last 6 months\n\nExclusion Criteria:\n\n* currently in treatment for psychosis or bipolar disorder\n* currently taking bupropion for non-smoking cessation reasons (e.g., Wellbutrin for depression)\n* currently pregnant or breastfeeding",{"count":274,"type":21},300,[24],"The goal of this clinical trial is to investigate how well nicotine pouches and nicotine mini lozenges serve as substitutes for cigarettes when people try to switch from smoking to using these alternate nicotine products.\n\nParticipants will:\n\n* Use nicotine pouches, nicotine mini lozenges, or no study product for a week and then try not to smoke for 3 weeks.\n* Have 6 in-person research visits and 1 follow-up call\n* Complete questionnaires at each study contact and use a smartphone app to record smoking and study product use",[278,28],"Smoker","2026-06-17",{"date":281,"type":34},"2026-06-22",{"date":283,"type":34},"2025-05-21",{"date":285,"type":21},"2029-07-30",{"name":98,"class":41},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":83,"sex":51,"minAge":84,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":296,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":42},"100561036","rural-smoking-cessation-100561036","NCT06584929","Rural Smoking Cessation","Evaluating Population-Based Strategies for Rural Smoking Cessation","Inclusion Criteria:\n\n* ≥ 21 years\n* smoke ≥ 5 cigarettes per day\n* daily access to their own iPhone\u002FAndroid smartphone or tablet\n\nExclusion Criteria:\n\n* past 30-day NRT use or contraindications listed on the NRT labels\n* currently pregnant\u002Fbreastfeeding",{"count":295,"type":21},272,[111],"Understanding ways to help people who live in rural areas quit smoking is a public health priority. quitting smoking among rural people who smoke is a critical public health concern. People in rural areas smoke at higher rates than those in urban areas, experience high rates of smoking caused cancers and deaths. We are recruiting rural people from around the country to better understand how different quit smoking methods can improve a person's chances of successfully quitting smoking.",[28],"2026-06-16",{"date":237,"type":34},{"date":302,"type":34},"2026-03-17",{"date":304,"type":21},"2029-08-31",{"name":306,"class":41},"Masonic Cancer Center, University of Minnesota",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":329,"locationsCount":42},"100642038","gen-ai-powered-behavioral-support-plus-chewing-gum-intervention-for-construction-workers-who-smoke-100642038","NCT07649018","Gen AI Powered Behavioral Support Plus Chewing Gum Intervention for Construction Workers Who Smoke","Build to Quit 「築建無煙」: Gen AI Powered Behavioral Support Plus Chewing Gum Intervention for Construction Workers Who Smoke: A Pragmatic, Pilot, Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n1. Hong Kong residents aged 18 or above\n2. Smoke at least one cigarette per day in the preceding 3-month\n3. Able to communicate in Cantonese (including reading and writing Chinese)\n4. Saliva cotinine 30 ng\u002Fml or above\n5. Intent to quit \u002F reduce smoking\n6. Have instant messaging tool (WhatsApp) installed\n7. Able to use instant messaging tool (e.g., WhatsApp) for communication.\n\nExclusion Criteria:\n\n1. Smokers who are participating in other smoking cessation programmes\n2. Smokers who are using any smoking cessation medication\n3. Smokers who are presenting with the following oral diseases, including recent oral surgery or tooth extraction, unstable dentures, significant tooth mobility or advanced periodontal disease, temporomandibular pain or dysfunction, or painful oral mucosal lesions",{"count":315,"type":21},200,[111],"The goal of this pilot trial is to learn if 1-week NRT sampling, 3-week chewing gum, and 12-week chatbot-delivered instant messaging support works to help smoking cessation in construction workers who smoke. It will also learn about the feasibility, acceptability, and preliminary effectiveness of delivering the comprehensive intervention in construction settings. The main questions it aims to answer are:\n\n1. Will the integrated intervention, comprising NRT sampling, chewing gum, and chatbot-delivered instant messaging support, show feasibility, acceptability, and appropriateness for delivery in construction worksite settings?\n2. Will participants who receive the comprehensive intervention have a higher validated abstinence rate than those who receive NRT sampling alone?\n\nResearchers will compare the integrated intervention, comprising NRT sampling, chewing gum, and chatbot-delivered instant messaging support, to the standard care group (NRT sampling alone) to see if the integrated intervention works to promote smoking cessation.\n\nParticipants in the intervention group will receive:\n\n1. AWARD advice and brief video\n2. 1-week NRT sampling\n3. 3-week chewing gum\n4. 12-week chatbot-based instant messaging support (via WhatsApp)",[28],[320,321,116,322,118,323],"Nicotine replacement therapy","Chewing gum","Large Language model","Construction worker","2026-06-14",{"date":279,"type":34},{"date":327,"type":21},"2026-06-20",{"date":213,"type":21},{"name":128,"class":41},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":22,"phases":339,"briefSummary":340,"conditions":341,"keywords":342,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":347,"leadSponsor":349,"locationsCount":42},"100642464","smoking-cessation-counseling-performance-among-medical-interns-100642464","NCT07650721","Smoking Cessation Counseling Performance Among Medical Interns","Effect of Artificial Intelligence-Assisted Interactive Case-Based Training on Smoking Cessation Counseling Performance Among Medical Interns","Inclusion Criteria:\n\n* Medical interns enrolled in the internship training program at the Faculty of Medicine, Assiut University during the study period.\n* Able to attend the training session and complete all study assessments, including the pre-test and post-test evaluations.\n\nExclusion Criteria:\n\n* Previous formal structured training in smoking cessation counseling based on the 5A model.\n* Previous participation in a smoking cessation counseling educational program within the preceding 12 months.\n* Failure to complete the assigned educational intervention.\n* Failure to complete either the pre-test or post-test assessment.\n* Withdrawal of consent at any stage of the study.",{"count":338,"type":21},140,[111],"Smoking remains one of the leading preventable causes of morbidity and mortality worldwide and is strongly associated with chronic respiratory diseases, cardiovascular disease, cancer, and premature death. Physicians play a central role in tobacco control through the delivery of smoking cessation counseling, and even brief physician advice has been shown to significantly increase smoking quit rates. The evidence-based 5A's model (Ask, Advise, Assess, Assist, and Arrange) is widely recommended as the standard framework for smoking cessation counseling.",[28],[28,343,344],"Artificial Intelligence","Medical Interns",{"date":299,"type":34},{"date":90,"type":21},{"date":348,"type":21},"2026-10-01",{"name":350,"class":41},"Assiut University",{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":83,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":42},"100532494","connecting-to-lungcare-100532494","NCT06213532","CONNECTing to LungCare","Inclusion Criteria:\n\n* English, Spanish and Cantonese speaking\n* Age \\>= 18 years old\n* Primary care patients at the University of California, San Francisco (UCSF) General Internal Medicine (GIM) clinics\n* Must be current smokers and\u002For candidates for Lung Cancer Screening (LCS).\n\nKey Informant Interviews:\n\n\\- Must be working in one of the clinics participating in CONNECTing to LungCare.\n\nExclusion Criteria:\n\n* Not a current smoker",{"count":358,"type":21},152,[111],"This study evaluates a smoking cessation intervention (CONNECTing to LungCare) for improving shared decision-making conversations about smoking cessation and lung cancer screening between patients and providers. Shared decision making is a patient care model in which providers offer information regarding risks and benefits, patients express their values and preferences, and then healthcare decisions are jointly discussed between the patient and provider. Patient education, aided by decision support tools, can increase patients' knowledge, decrease their decisional conflict, promote decision making, and improve the patients' perception of risk. CONNECTing to LungCare is an interactive education intervention that addresses lung cancer screening and smoking cessation and provides participants with a tailored summary that may make them more likely to have shared decision-making discussions with their providers about smoking cessation and lung cancer screening.",[28,362,363],"Cigarette Smoking-Related Carcinoma","Lung Carcinoma",{"date":365,"type":34},"2026-06-15",{"date":367,"type":34},"2024-12-03",{"date":369,"type":21},"2026-11-30",{"name":371,"class":41},"University of California, San Francisco",{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":22,"phases":381,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":42},"100487538","phone-enabled-implementation-of-cessation-support-100487538","NCT05628389","Phone Enabled Implementation of Cessation Support","PHOENICS","Inclusion Criteria:\n\n* Age 18+\n* A current daily cigarette smoker and\u002For a regular waterpipe smoker (smokes at least 1-2 times\u002Fweek).\n* Not pregnant\n* Reachable by phone\n* Interested in quitting\n* Lives in Greater Beirut Area\n\nExclusion Criteria:\n\n* Patients who use other tobacco products including vape exclusively.\n* Any patient below 18 years old.\n* Cigarette smokers who do not smoke on daily basis.\n* Waterpipe smokers who smoke less than once\u002Fweekly",{"count":380,"type":21},1500,[111],"The tobacco use burden in Lebanon is exceptionally high: 35% of adults are current cigarette smokers and 39% are current waterpipe smokers. Although the World Health Organization endorses evidence-based interventions for population-level tobacco dependence treatment, recommended treatments are not integrated as a routine part of primary care in Lebanon, as is the case in other low-resource settings. The objective of this proposal is to evaluate the comparative effectiveness of promising multi-component interventions for implementing evidence-based cessation treatment in Lebanon's national system of primary health care centers.",[28],"2026-06-10",{"date":386,"type":34},"2026-06-12",{"date":388,"type":34},"2024-03-06",{"date":390,"type":21},"2027-08-31",{"name":392,"class":41},"University of Florida",{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":22,"phases":403,"briefSummary":404,"conditions":405,"keywords":407,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":417,"locationsCount":42},"100470996","phase-2-evaluating-smoking-cessation-interventions-for-pwh-in-south-africa-100470996","NCT05413122","Evaluating Smoking Cessation Interventions for PWH in South Africa","Evaluating Smoking Cessation Interventions for PWH in South Africa: Efficacy, Implementation, and Cost-effectiveness","Tlogela","Inclusion Criteria:\n\n1. ≥18 years of age, and\n2. attend one of the selected study clinics, and\n3. have a confirmed diagnosis of HIV (evidenced by one of: clinic or hospital prescription for combination antiretroviral therapy (ART), or a current ART medication pack that has the patient's name documented thereon) and\n4. have been taking ART for at least three consecutive months or evidence of taking ART for four of the past six months (to ensure engagement in care at the recruitment clinic), and\n5. are current tobacco smokers (smoked at least 100 cigarettes in the subject's lifetime, smoked at least one cigarette daily in the past 30 days, have exhaled breath carbon monoxide (CO) ≥ 7 parts per million (ppm), and have a positive urine cotinine test), and\n6. either own or have household access to a mobile phone, and\n7. provide written informed consent.\n\nExclusion Criteria:\n\n1. Currently (within the previous 14 days) receiving or using smoking cessation counselling or pharmacotherapy, or\n2. are unable to participate due to severity of medical illness, guided by a Karnofsky score of ≤ 40, or\n3. have a history of seizures, cancer, heart disease, stroke, myocardial infarction, stomach ulcers, kidney failure, or liver failure, or\n4. have generalized eczema or psoriasis, or\n5. have cognitive dysfunction or psychosis as defined by the Mini-International Neuropsychiatric Interview (M.I.N.I.), or\n6. have suicide risk as defined by the Columbia-Suicide Severity Rating Scale (C-SSRS), or\n7. are pregnant, planning to become pregnant in the next four months, lactating, or are unwilling to use effective birth control, or\n8. have a history of adverse reactions to varenicline or nicotine patch, or\n9. are not planning to continue to receive care at the clinic for the next 52 weeks, or\n10. are a household member of a currently enrolled participant in this trial, or\n11. In the opinion of the attending investigator are not a candidate for the clinical trail.",{"count":402,"type":21},660,[225,226],"The overall objective of the study is to optimize a smoking cessation treatment package for people with HIV (PWH) that can be integrated into existing HIV care in South Africa.",[28,164,406],"Comorbidities and Coexisting Conditions",[28,408,66,409,410],"Combination NRT","Behavioral Counselling","Peer Counseling","2026-06-05",{"date":413,"type":34},"2026-06-09",{"date":415,"type":34},"2023-11-27",{"date":390,"type":21},{"name":418,"class":41},"Johns Hopkins University",{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":51,"minAge":84,"maxAge":52,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":428,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":440,"leadSponsor":441,"locationsCount":4},"100642885","phase-2-thcv-treatment-for-smokers-100642885","NCT07636356","THCV Treatment for Smokers","Development of Tetrahydrocannabivarin as a Treatment for Smokers","Inclusion Criteria:\n\n1. Be between the ages of 21 and 65;\n2. Smoke 10 or more combustible cigarettes per day;\n3. Have fewer than 3 months of smoking abstinence in the past year;\n4. Has self-reported ≥10 lifetime uses of cannabis products;\n5. Have self-reported recent (past 3-month) use of cannabis products;\n6. Agree to abstain from all other cannabinoid use during the study;\n7. Agree to abstain from all other medication use during the study, other than methods of birth control as listed in inclusion criteria for female participants;\n8. Agree to one of the following methods of birth control (if female), unless she or partner are surgically sterile: oral contraceptives, Contraceptive sponge, patch, double barrier, intrauterine contraceptive device, etonogestrel implant, medroxyprogesterone acetate contraceptive injection, hormonal vaginal contraceptive ring, complete abstinence from sexual intercourse.\n\nExclusion Criteria:\n\n1. Have current (last 12 months) DSM-5 diagnosis of substance use disorder for any psychoactive substances other than nicotine;\n2. Have a lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any other psychotic disorder;\n3. Have a score of 3 or greater on the Columbia Suicide Severity Rating Scale (C-SSRS) at screening or anytime during study participation;\n4. Have a positive urine screen for any substances, including cannabis\n5. Have a breathalyzer reading above 0.000 g\u002Fdl;\n6. Be pregnant, nursing, or planning to become pregnant while taking part in the study;\n7. Have a medical condition that may interfere with safe study participation;\n8. Have clinically significant abnormalities on the EKG;\n9. Have evidence of renal impairment, defined by an eGFR value of \\\u003C90 ml\u002Fmin;\n10. Have evidence of hepatic impairment, defined by a score of ≥5 points on the Child-Pugh assessment of liver function;\n11. Exceed Grade 2 laboratory or vital sign abnormalities, based on FDA Guidance Document \"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials\";\n12. Have past month use of cannabis or cannabis products;\n13. Have past month use of electronic nicotine delivery system (ENDS);\n14. Have use of any medications (other than methods of birth control as listed in inclusion criteria for female participants) within 14 days or 5 half-lives (whichever is longer) prior to study drug administration, and throughout the study, including medication for smoking cessation, any prescription, OTC, dietary supplements, herbal products, or vitamins;\n15. Have any other circumstances that, in the opinion of the investigators, would not be a good fit for study participation.",{"count":427,"type":21},32,[225],"This study will randomize 32 non-treatment-seeking individuals who smoke cigarettes daily into a randomized, crossover, double-blind, placebo-controlled study testing the safety, tolerability, and initial efficacy of Δ9-tetrahydrocannabivarin (Δ9-THCV).",[431,28],"Tobacco Use Disorder",[433,434,207,435,436],"smoking cessation","tobacco use disorder","THCV","Tetrahydrocannabivarin","2026-06-02",{"date":413,"type":34},{"date":94,"type":21},{"date":262,"type":21},{"name":442,"class":41},"University of California, Los Angeles",{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":83,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":22,"phases":452,"briefSummary":453,"conditions":454,"keywords":456,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":42},"100596767","healthy-family-project-tobacco-use-and-smoke-exposure-in-asian-american-communities-100596767","NCT07049757","Healthy Family Project: Tobacco Use and Smoke Exposure in Asian American Communities","Healthy Family Project: Ending Tobacco Use and Smoke Exposure in Asian American Communities","Inclusion Criteria:\n\nAll Participants (Lay Health Workers, Smokers, Family Participants, and Post-Trial Household Member Group Interview Participants):\n\n1. Must be 18 years of age or older.\n2. Must self-identify as Chinese or of Chinese descent (ethnic or cultural identification, not national origin).\n3. Must be able to understand in spoken Chinese (Cantonese and\u002For Mandarin) or English.\n4. Able to attend educational sessions in person or via video conferencing.\n5. Ability to understand and the willingness to sign a written informed consent document.\n6. Have a mobile phone that can receive Short Message Service (SMS) text messages, or an email address and a phone number where they can be reached by the study team.\n\nLay Health Workers:\n\n1. Must have experience or interest in community outreach and education.\n2. Must demonstrate proficiency in language (Cantonese and\u002For Mandarin or English) sufficient to deliver study materials and interact with participants.\n3. Must be affiliated with the Chinese Community Health Resource Center (CCHRC) or recruited through community networks.\n4. Must agree to participate in training and intervention delivery activities as outlined in the study protocol.\n\nSmokers (Participants who are current smokers):\n\n1. Must have smoked within the past 30 days, either daily or occasionally.\n2. Must have a non-smoking household member.\n\nFamily Participants (Non-smoking family\u002Fhousehold members):\n\n1. Must live in the same household as the smoker participant.\n2. Must not have used any tobacco products in the past 30 days.\n\nPost-Trial Household Member Group Interview Participants:\n\n1\\. Living in the same household with the smoker-household member dyad participant being interviewed or considered as a household member.\n\nExclusion Criteria:\n\nLay Health Workers, Smokers (Participants who are current smokers) and Family Participants (Non-smoking Family\u002Fhousehold members):\n\n1. Currently participating in another smoking cessation program.\n2. Non-residents of California.\n3. Participants unwilling to provide follow-up contact for assessments at 6 and 12 months.\n\nLay Health Workers:\n\n1. Lack of willingness or ability to complete training or deliver intervention sessions as required by the study protocol.\n2. Inability to maintain confidentiality and professionalism during interactions with study participants.\n3. Active participation in conflicting research studies or programs.",{"count":451,"type":21},760,[111],"This study evaluates whether the Smokefree Family Living (SFL) intervention improves quit rates (smoking cessation) and exposure to tobacco contamination that stays in items such as, carpets, walls, and furniture, even after the smoke has cleared (third-hand smoke (THS)) among Chinese American smokers and their non-smoking household members. Smoking remains high among Chinese American males with limited ability to speak English. This causes the non-smoking household members to be exposed to THS, which contains many of the same harmful components as smoking and becomes more toxic as it ages. SFL is tailored for Chinese Americans and combines the contents of the Quit Smoking for a Healthy Family (QS) intervention with additional THS education and cleaning strategies. QS focuses on smoking cessation through educational sessions and support. THS education and cleaning strategies provide information on THS and how to clean the home for THS. SFL may help Chinese American smokers and their non-smoking household members learn about the importance of quitting and the dangers of THS, this may improve smoking cessation and reduce THS exposure",[455,28],"Tobacco-Related Carcinoma",[457],"Third-hand Smoke",{"date":459,"type":34},"2026-06-04",{"date":461,"type":34},"2026-03-23",{"date":463,"type":21},"2028-09-30",{"name":371,"class":41},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":22,"phases":474,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":481,"leadSponsor":482,"locationsCount":42},"100637102","llm-intervention-for-tobacco-in-underserved-populations-lift-up-100637102","NCT07620301","LLM Intervention for Tobacco in Underserved Populations (LIFT-UP)","LIFT-UP","Inclusion Criteria:\n\n* 18+ years old\n* Use ≥3 cigarettes\u002Fday on average\n* Motivated to quit in the next 30 days\n* Have a computer or tablet with internet access for 1:1 interviews\n* Speak English or Spanish\n* Home address is in an area characterized by persistent poverty\n\nExclusion Criteria:\n\n* None",{"count":473,"type":21},22,[111],"This study will test a tailored, multilingual tobacco cessation chatbot called LIFT-UP (LLM Intervention for Tobacco in Underserved Populations), designed to better meet the needs of people living in persistent poverty census tracts.\n\nThis study will use 1:1 semi-structured interviews to explore social drivers of health impacting TC, as well as digital access and preferences among those living in PPCTs. This qualitative approach enables guided yet flexible exploration of key domains while capturing unanticipated insights relevant to refining the chatbot.",[28],"2026-06-01",{"date":479,"type":34},"2026-06-03",{"date":477,"type":21},{"date":242,"type":21},{"name":483,"class":41},"University of Utah",{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":51,"minAge":491,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":22,"phases":494,"briefSummary":495,"conditions":496,"keywords":497,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":505,"leadSponsor":506,"locationsCount":42},"100641274","3a-or-very-brief-tobacco-cessation-intervention-in-primary-care-100641274","NCT07609199","3A-OR Very Brief Tobacco Cessation Intervention in Primary Care","The Effectiveness of the 3A-OR Very Brief Tobacco Cessation Intervention in Primary Care: A Multicenter Pragmatic Trial Protocol","Inclusion Criteria:\n\n1. Being aged 15 years and older (including pregnant and breastfeeding women);\n2. Having used any tobacco product at least once daily within the last month;\n3. All smokers, regardless of their intention to quit tobacco use;\n4. Providing a phone number for follow-up;\n5. Being able to read and speak Turkish;\n6. Signing the informed consent form.\n\nExclusion Criteria:\n\n1. Using tobacco products less than once per day;\n2. Having made an attempt to quit tobacco use within the last month;\n3. Having impaired cognitive functions;\n4. Having participated in another study on tobacco use within the past year.","15 Years",{"count":493,"type":21},2400,[111],"Introduction: Türkiye is far from the World Health Organization (WHO)'s target of reducing tobacco use prevalence by 30% by 2025. Most tobacco users consider quitting, and most have attempted to quit at least once. However, the success rate of quitting on one's own is quite low. Studies demonstrating that very brief tobacco cessation interventions delivered by healthcare professionals increase cessation rates have almost entirely been conducted in hospital settings. The aim of this trial is to investigate the effectiveness of implementing the 3A-OR (Ask - Assess - Advise - Offer Assistance - Record) very brief tobacco cessation intervention in routine primary care family medicine practice on the success of tobacco cessation.\n\nMethods\u002Fdesign: This protocol describes a two-arm, multicenter pragmatic trial for adolescent and adult tobacco users. The project will be carried out in family health centers in 21 study sites across the 12 statistical regions of Türkiye. In the intervention arm, volunteer family physicians will implement the 3A-OR very brief tobacco cessation intervention to their patients as part of their routine clinical practice. The intervention consists of the following steps: 'asking patients about their tobacco use status', 'assessing users' motivation to quit', 'advising quitting based on their motivation status', 'offering cessation assistance', and 'recording information regarding patients' tobacco use status and repeating the intervention at each patient contact'. Routine practice in family health centers will constitute the control group. Data will be collected using standard questionnaire forms at baseline and during follow-up interviews at 3, 6, and 12 months. Tobacco cessation rate and increase in smokers' motivation were the primary outcomes of the trial.\n\nDiscussion: If the 3A-OR very brief tobacco cessation intervention is found to be effective, the results of this trial will provide evidence that will encourage the widespread use of the intervention in primary care family health centers. The study results are intended to be disseminated through the Family Medicine Academy Association website, conference presentations, and scientific publications.",[28],[498,433,499,500],"pragmatic clinical trial","primary health care","brief intervention","2026-05-21",{"date":503,"type":34},"2026-05-27",{"date":477,"type":21},{"date":213,"type":21},{"name":507,"class":41},"Aydin Adnan Menderes University",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":83,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":515,"targetDuration":4,"studyType":22,"phases":516,"briefSummary":517,"conditions":518,"keywords":519,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":526,"leadSponsor":528,"locationsCount":42},"100599039","chatgpt-supported-text-messaging-program-for-smoking-cessation-100599039","NCT07079306","ChatGPT-Supported Text Messaging Program for Smoking Cessation","Engagement and Satisfaction With a ChatGPT-Supported Text Messaging Program for Smoking Cessation","Inclusion Criteria:\n\n* lives in the US\n* smoked a cigarette within the last 7 days\n* has a mobile phone\n* willing to receive text messages about the health effects of smoking on their mobile phone for 30 days\n\nExclusion Criteria:\n\n* none",{"count":223,"type":21},[111],"The current research proposal aims to explore how a purpose driven LLM ChatGPT chatbot, BeFreeBot, might enhance an evidence-based text messaging smoking cessation program, BeFree. The research will consist of a formative evaluation comparing quitting related outcomes among users of BeFree+Bot and BeFree.",[28],[433,520,521],"ai","text messaging","2026-05-20",{"date":524,"type":34},"2026-05-22",{"date":348,"type":21},{"date":527,"type":21},"2027-01-30",{"name":529,"class":41},"George Washington University",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":51,"minAge":84,"maxAge":52,"enrollmentInfo":537,"targetDuration":4,"studyType":22,"phases":538,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":555},"100641102","phase-2-multi-site-trial-of-tirzepatide-for-smoking-cessation-100641102","NCT07602699","Multi-Site Trial of Tirzepatide for Smoking Cessation","A Multi-Site Trial of Tirzepatide for Smoking Cessation","Inclusion Criteria:\n\n1. Age 21-65 years\n2. Body mass index ≥ 25kg\u002Fm2 at the baseline screening\n3. Reporting ≥10 cigarettes per day, on average, for the past 6 months and \\> 2 year duration of smoking\n4. Interest in making a long-term cessation attempt within the next 30-60 days\n5. Willingness to receive study medication and standard-of-care smoking cessation supports (nicotine replacement therapy and a smoking cessation app)\n6. Ability to adhere to weekly visits and study procedures over the study period (i.e., no plans to move or travel for extended periods)\n7. Exhaled CO of \\>5ppm at baseline\n8. Use of an acceptable birth control method for female participants\\*\n9. Ability to read and communicate in English\n\nExclusion Criteria:\n\n1. BMI \\\u003C 25 kg\u002Fm2 at screening\n2. History of diabetes, diabetes-attributable medical conditions, or HbA1c ≥6.5% at baseline\n3. Recent (past 90 days) active suicidal ideation or lifetime history of suicide attempt\n4. Current treatment for psychotic disorders or mood disorders with psychotic features (e.g., schizophrenia, schizoaffective disorder, depression with psychotic features), current treatment for bipolar disorder (with or without psychotic features), or current secondary psychosis due to substance use or another medical condition\n5. Meeting DSM-5 criteria for a current (past 12 months) substance use disorder other than tobacco use disorder, mild or moderate cannabis use disorder, or mild or moderate alcohol use disorder.\n6. Recent (past 30 day) self-report of illicit drug use (excluding cannabis) or non-prescribed opioids; or positive urine screen for illicit drugs. A positive screen for opioids will be allowed if the participant is prescribed an opioid replacement therapy medication and can provide documentation.\n7. Past 30-day initiation of psychiatric medications (e.g., SSRIs) or changes to medication dose\n8. Treatment with tirzepatide or another GLP-1RA medication in the prior 6 months\n9. Current (past month) treatment with other weight loss, diabetes, or smoking cessation medications (varenicline or bupropion; excluding nicotine replacement products)\n10. Severe GI disease (e.g., gastroparesis, ulcerative colitis).\n11. History of gastric bypass surgery or other surgeries of the stomach\n12. Any health condition or treatment\u002Fmedication that would preclude the use of tirzepatide or NRT, in the opinion of the study physician, including severe cardiovascular disease\n13. History of chronic pancreatitis or acute pancreatitis in the last 6 months\n14. Currently nursing, pregnant, or anticipating pregnancy\n15. History of diabetic retinopathy, proliferative retinopathy, or maculopathy\n16. Elevated serum lipase, amylase, bilirubin, or ALP, ALT, or AST (\\>5x upper limit of normal range)\n17. History of malignant neoplasms in the last 5 years, except non-melanoma skin cancer\n18. Inability to attend weekly clinic visits as scheduled (i.e., based on travel or work schedule)\n19. Currently enrolled in another clinical study involving an investigational product\n20. Currently living in the same household as someone taking a GLP-1 medication, or living with a current or former participant in the present trial\n21. Planned surgical procedures requiring anesthesia during the planned study medication period\n22. Personal or family history of medullary thyroid cancer\n23. Personal or family history of multiple endocrine neoplasia syndrome type 2 (MEN 2)\n24. Treatment with other weight loss (e.g., phentermine), or FDA-approved, non-NRT smoking cessation therapies (varenicline, bupropion) or FDA-approved AUD medications (naltrexone, acamprosate, disulfiram) or off-label AUD medications (e.g., topiramate) in the past 90 days\n25. Any health condition or treatment\u002Fmedication that would preclude use of tirzepatide or NRT, in the opinion of the site physicians including thyroid enlargement.",{"count":274,"type":21},[225],"This multi-site clinical trial will generate data on the efficacy of tirzepatide for smoking cessation and associated outcomes (e.g., post-cessation weight gain) in treatment-seeking people who smoke (PWS) with overweight or obesity. A sample of 300 treatment-seeking people who smoke with body mass index of 25 kg\u002Fm2 or greater will be recruited from four geographic sites (University of Southern California, Yale University, University of Chicago, and University of Colorado Anschutz Medical Campus) to participate in a parallel-arm, dose-escalating, placebo-controlled trial. Participants will attend weekly clinic visits to receive subcutaneous tirzepatide or placebo over 16 weeks (Visit Weeks 1-16), followed by follow-up visits at Week 17 and Week 27. Medication will be prescribed according to the standard dose titration schedule for the first 16 weeks of treatment (initial dose: 2.5mg\u002Fweek; final dose: 10mg\u002Fweek). All participants will also receive nicotine patches.",[28,541],"Smoking Behaviors",[543,544,545,546],"Addiction","GLP-1","Tirzepatide","Substance Use Disorder","2026-05-18",{"date":524,"type":34},{"date":550,"type":21},"2026-05-31",{"date":552,"type":21},"2028-09",{"name":554,"class":41},"University of Southern California",4,{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":83,"sex":51,"minAge":564,"maxAge":565,"enrollmentInfo":566,"targetDuration":4,"studyType":22,"phases":568,"briefSummary":569,"conditions":570,"keywords":574,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":578,"leadSponsor":580,"locationsCount":42},"100601549","evaluating-the-impact-of-connect-in-a-multilingual-population-100601549","NCT07111936","Evaluating the Impact of CONNECT in a Multilingual Population","Evaluating the Impact of CONNECT, a Novel Smoking Cessation Intervention, in a Diverse, Multilingual Population","CONNECT-ML","Inclusion Criteria:\n\n* Age 50-80 years old.\n* Current smokers defined at smoking at least one cigarette in past 7 days AND eligible for lung cancer screening (LCS) based on smoking history (\\>=20 pack year history)\n* California (CA) residents\n* Able to understand and comply with study procedures for the entire length of the study.\n* Ability of individual or legal guardian\u002Frepresentative to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n* Non-smokers.\n* Individuals with a diagnosis of lung cancer.\n* Individuals receiving hospice care.\n* Individuals whose providers do not think that they should participate (e.g., psychiatric illness or significant cognitive impairment that would impede the individuals ability to participate).\n* Hearing and\u002For vision disabilities that would prevent participants from adequately receiving treatment components such as video or telephone counseling.","50 Years","80 Years",{"count":567,"type":21},439,[111],"This study aims to broaden the reach of the lung cancer screening (LCS) CONNECT program (NCT04149249, NCT06213532), by developing a version of the program to be available to multilingual communities. The CONNECT program encourages individuals who are undergoing lung cancer screening to also quit smoking by providing a personalized program which includes a video doctor with personalized responses, text message and telephone call support and connection with a pharmacist to assist in obtaining nicotine replacement medication. This clinical trial will develop and ultimately test how well the CONNECT Multilingual (CONNECT ML) program works to improve smoking cessation among current adult smokers within the Spanish and Cantonese speaking communities.",[28,571,572,573],"Smoking Cessation Counseling Ability and Practice","Smoking Cessation Counselling","Lung Cancer Screening",[575],"Multilingual",{"date":524,"type":34},{"date":92,"type":21},{"date":579,"type":21},"2028-03-31",{"name":371,"class":41},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":83,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":22,"phases":590,"briefSummary":591,"conditions":592,"keywords":594,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":601,"leadSponsor":603,"locationsCount":42},"100627361","testing-an-mbi-for-smoking-cessation-and-alcohol-use-among-cancer-survivors-100627361","NCT07447635","Testing an MBI for Smoking Cessation and Alcohol Use Among Cancer Survivors","Smoking Cessation and Alcohol Use Among Cancer Survivors: Investigating the Efficacy of a Mindfulness-Based Intervention","Inclusion Criteria:\n\n* ≥18 years old\n* History of a cancer diagnosis at any point in lifetime\n* Smoked ≥1 cigarette\u002Fday in past month\n* At least one binge drinking episode in past month or exceeds weekly drinking limits\n* Motivated to quit smoking and modify alcohol use in next 30 days\n* Valid home address in Florida\n* English-speaking, reading, and writing ability\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Active psychotic disorder\n* History of severe alcohol withdrawal\n* Current use of tobacco cessation medication or other treatments to quit smoking\n* End-of-life or hospice care\n* Household member already enrolled",{"count":589,"type":21},600,[111],"This study will examine the efficacy of Mindfulness-Based Relapse Prevention for Smoking and Alcohol (MBRP-SA) compared to standard care among cancer survivors who smoke cigarettes and engage in at-risk alcohol use. Investigators will evaluate implementation outcomes through structured stakeholder interviews across medical centers, cancer-focused organizations, and community-based programs in Florida, and will conduct a cost-assessment and an incremental cost-effectiveness analysis of the two conditions.",[28,593],"Alcohol Use",[595,596,117,597],"Mindfulness-based intervention","Cancer survivors","Alcohol use","2026-05-15",{"date":547,"type":34},{"date":598,"type":34},{"date":602,"type":21},"2029-12",{"name":172,"class":41}]